Alerts

We are reviewing the safety of the Pneumovax 23 vaccine due to reports of severe local reactions and have updated our revaccination recommendations.

Concerns have been expressed that a range of breast screening devices based on technologies other than mammography have not been appropriately assessed for their safety or accuracy.

On 26 January 2011, the US Food and Drug Administration (FDA) announced a safety communication to warn about an association between breast implants and anaplastic large cell lymphoma. The risk of a patient developing this type of lymphoma is very low.

We are recalling Thelin (sitaxentan) worldwide due to serious liver risks. Consult your doctor if you have concerns.

Seasonal flu vaccine: Response to the West Australian (Stokes) Review

Do not use So Hard for Men tablets, Shaguar tablets, and Pulse8 for Women capsules as they contain undeclared tadalafil and are not approved. Consult your doctor if you have concerns.

Weight loss drug Sibutramine (Reductil) withdrawn in Australia due to heart risks.

About Brachytherapy kits (regulatory status)

The national immunisation program with Panvax® began on 30 September 2009. The TGA has been closely monitoring any side effects from the use of the vaccine.

The Therapeutic Goods Administration (TGA) has received enquiries about the recall of the LCS® DuofixTM Femoral Knee Replacement Component.

The TGA is aware that the French authorities have now released an updated statement in regard to the testing of the PIP implants:

We are analysing the safety of the Panvax H1N1 vaccine following reports of febrile convulsions in children.